Common Stock
- Symbol
- VBIO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Valion Bio, Inc.
VBIONASDAQEQUITYCurrent
Other Events
Item 8.01. Other Matters. On October 5, 2026, Valion Bio, Inc. (the “Company”) issued a press release highlighting the expertise and goals of new board chair, Thomas Jensen as relating to the future of the Company. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.
Press release in this filing
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod →Company context
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise generally applicable to public companies. As a result:
Current securities
Historical securities (1)
Registered securities in this filing
Valion Bio, Inc. · 8-K · Filed 2026-10-06
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Matters.
On October 5, 2026, Valion Bio, Inc. (the “Company”) issued a press release highlighting the expertise and goals of new board chair, Thomas Jensen as relating to the future of the Company.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.